The results of severe acute pancreatitis treatment with continuous regional arterial infusion of protease inhibitor and antibiotic: A randomized controlled study

Pancreas

Volumn 39, Issue 6, 2010, Pages 863-867

  Piaścik, Marta ^a   Rydzewska, Grazyna ^a   Milewski, Janusz ^a   Olszewski, Stanisław ^a   Furmanek, Mariusz ^a   Walecki, Jerzy ^a   Gabryelewicz, Antoni ^b  

^a Central Hospital of the Internal Affairs and Administration Ministry   (Poland)

^b MEDICAL UNIVERSITY OF BIALYSTOK   (Poland)

Author keywords

antibiot; continuous regional arterial infusion; protease inhibitors; severe acute pancreatitis

Indexed keywords

ANTIBIOTIC AGENT; IMIPENEM; NAFAMSTAT MESILATE;

ACUTE PANCREATITIS; ADULT; ARTERY PERFUSION; ARTICLE; CLINICAL TRIAL; CONTINUOUS INFUSION; CONTINUOUS REGIONAL ARTERIAL INFUSION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE SEVERITY; DRUG ADMINISTRATION; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERANCE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MORTALITY; PANCREAS ABSCESS; PANCREAS NECROSIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SEPSIS; SEVERE ACUTE PANCREATITIS; UNSPECIFIED SIDE EFFECT;

ACUTE DISEASE; ANTI-BACTERIAL AGENTS; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; FEMALE; GUANIDINES; HUMANS; IMIPENEM; INFUSIONS, INTRA-ARTERIAL; INFUSIONS, INTRAVENOUS; MALE; MIDDLE AGED; PANCREATITIS; PROTEASE INHIBITORS; SEVERITY OF ILLNESS INDEX; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 77955220276     PISSN: 08853177     EISSN: None     Source Type: Journal    
DOI: 10.1097/MPA.0b013e3181d37239     Document Type: Article

References (28)

1. Go VL, Everhart JE. Pancreatitis. In: Everhart JE, ed. Digestive Diseases in the United States: Epidemiology and Impact. US Department of Health and Human Services, Public Health Service, National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases. Washington, DC: US Government Printing Office; 1994: p. 693. NIH Publication no. 94-1447.
2. Bradley EL 3rd. A clinically based classification system for acute pancreatitis. Summary of the International Symposium on Acute Pancreatitis, Atlanta, GA, September 11 through 13, 1992. Arch Surg. 1993;128:586-590.
3. Bradley EL. The necessity for a clinical classification of acute pancreatitis: the Atlanta System. In: Bradley EL, ed. Acute Pancreatitis: Diagnosis and Therapy. New York, NY: Raven Press; 1994;4:27-32.
4. Inoue K, Hirota M, Beppu T, et al. Angiographic features in acute pancreatitis: the severity of abdominal vessel ischemic change reflect the severity of acute pancreatitis. JOP. 2003;4(6):2007-2213.
5. Baron TH, Morgan DE. Acute necrotizing pancreatitis. N Engl J Med. 1999;340:1412-1417.
6. Neoptolemos JP, Rarety M, Finch M, et al. Acute pancreatitis: the substantial human and financial costs. Gut. 1998;42:886-891.
7. Takeda K, Matsuno S, Sunamura M, et al. Continuous regional arterial infusion of protease inhibitor and antibiotic in acute necrotizing pancreatitis. Am J Surg. 1996;171:394-398.
8. Mikami Y, Takeda K, Matsuda K, et al. Rat experimental model of continuous regional arterial infusion of protease inhibitor and its effects on severe acute pancreatitis. Pancreas. 2005;30:248-253.
9. Yamauchi J, Takeda K, Shibuya K, et al. Continuous regional application of protease inhibitor in the treatment of acute pancreatitis. An experimental study using closed duodenal obstruction model in dogs. Pancreatology. 2001;1:662-667.
10. Mayumi T, Takada T, Kawarada Y, et al. JPN guidelines for the management of acute pancreatitis: cutting-edge information. J Hepatobiliary Pancreat Surg. 2006;13:2-6. (Pubitemid 43193668)
11. Takeda K, Matsuno S, Ogawa M, et al. Continuous regional arterial infusion (CRAI) therapy reduces the mortality rate of acute necrotizing pancreatitis: results of cooperative survey in Japan. J Hepatobiliary Pancreat Surg. 2001;8(3):216-220.
12. Imaizumi H, Kida M, Nishimaki H, et al. Efficacy of continuous regional arterial infusion of protease inhibitor and antibiotic for severe acute pancreatitis in patients admitted to an intensive care unit. Pancreas. 2004;28(4):369-373.
13. Takeda K. Antiproteases in the treatment of acute necrotizing pancreatitis: continuous regional arterial infusion. JOP. 2007; 8(suppl 4):526-532.
14. Skyring A, Singer A, Tornya P. Treatment of acute pancreatitis with Trasylol: report of controlled therapeutic trial. BMJ. 1965;5462: 627-629.
15. Baden H, Jordal K, Lund F, et al. A double-blind controlled clinical trial of Trasylol. Preliminary results in acute pancreatitis and in prophylaxis against postoperative pancreatitis. Acta Chir Scand. 1967;378(suppl):97-102.
16. Imrie CW, Benjamin IS, Ferguson JC, et al. A single-centre double-blind trial of Trasylol therapy in primary acute pancreatitis. Br J Surg. 1978;65:337-341.
17. Büchler M, Malfertheiner P, Uhl W, et al. Gabexate mesilate in human acute pancreatitis. German Pancreatitis Study Group. Gastroenterology. 1993;104:1165-1170.
18. Valderrama R, Perez-Mateo M, Navarro S, et al. Multicenter double-blind trial of gabexate mesilate (FOY) in unselected patients with acute pancreatitis. Digestion. 1992;51:65-70.
19. Yang CY, Chang-Chien CS, Liaw YF. Controlled trial of protease inhibitor gabexate mesilate (FOY) in the treatment of acute pancreatitis. Pancreas. 1987;2:698-700.
20. Chen HM, Chen JC, Hwang TL, et al. Prospective and randomized study of gabexate mesilate for the treatment of severe acute pancreatitis with organ dysfunction. Hepatogastroenterology. 2000;47:1147-1150.
21. Watanabe S. Acute pancreatitis: overview of medical aspects. Pancreas. 1998;16:307-311.
22. Takeuchi T, Takabe T, Sato T. Clinical evaluation of FUT-175 (nafamostat mesilate) on pancreatitis. A double-blind controlled study with gabexate mesilate. Digest Med. 1984;1:255-270.
23. Yamamura H, Tamakuma S, Nakashima M. Clinical evaluation of MR-20 on shock. A double-blind controlled study with aprotinin. J Clin Exp Med. 1984;129:730-738.
24. Tsukagosi S. Pharmacokinetics studies of nafamostat mesilate (FUT), a synthetic protease inhibitor, which has been used for treatment of DIC and acute pancreatitis, and as an anticoagulant in extracorporeal circulation [in Japanese]. Gan To Kagaku Ryoho. 2000;27:767-774.
25. Takeda K, Mikami Y, Fukuyama S, et al. Pancreatic ischemia associated with vasospasm in the early phase of human acute necrotizing pancreatitis. Pancreas. 2005;30:40-49.
26. Isenmann R, Runzi M, Kron M, et al. German antibiotics in severe acute pancreatitis study group. Gastroenterology. 2004;126(4):997-1004.
27. Dellinger EP, Tellado JM, Soto NE, et al. Early antibiotic treatment for severe acute necrotizing pancreatitis: a randomized, double-blind, placebo-controlled study. Ann Surg. 2007;245:674-683.
28. Ino Y, Arita Y, Akashi T, et al. Continuous regional arterial infusion therapy with gabexate mesilate for severe acute pancreatitis. World J Gastroenterol. 2008;14(41):6382-6387.